Life AI Net
Accueil
Archives
Calculateurs
Annuaire
Newsletter
Hot
Connexion
Français
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Accueil
Archives
Calculateurs
Annuaire
Newsletter
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Connexion
Accueil
Archives
Calculateurs
Annuaire
More
Live
Cell
A skin-hypothalamus axis couples heat stress and metabolic dysfunction
Cell
The evolution of high-order genome architecture revealed from 1,000 species
Cell
Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states
Cell
Pyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylation
Cell
Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets
BD
Area Softball: PRB gets 2 wins - Brainerd Dispatch
FierceBiotech
WCG acquires The Contract Network in bid to streamline clinical trial execution
Recursion
Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com Canada
Recursion
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
Recursion
[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
Cell
A skin-hypothalamus axis couples heat stress and metabolic dysfunction
Cell
The evolution of high-order genome architecture revealed from 1,000 species
Cell
Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states
Cell
Pyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylation
Cell
Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets
BD
Area Softball: PRB gets 2 wins - Brainerd Dispatch
FierceBiotech
WCG acquires The Contract Network in bid to streamline clinical trial execution
Recursion
Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com Canada
Recursion
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
Recursion
[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
Archives
Rechercher
Rechercher
Récent
Plus ancien
Effacer
@BioWorld
Total
1090
Source
BioWorld
Recherche
--
BioWorld
2 déc. 2025
New CDK inhibitors disclosed in Adlai Nortye patent
BioWorld
2 déc. 2025
Alebund Pharmaceuticals discovers new complement factor B inhibitors
BioWorld
1 déc. 2025
Appointments and advancements for Dec. 1, 2025
BioWorld
1 déc. 2025
Financings for Dec. 1, 2025
BioWorld
1 déc. 2025
In the clinic for Dec. 1, 2025
BioWorld
1 déc. 2025
Other news to note for Dec. 1, 2025
BioWorld
1 déc. 2025
Regulatory actions for Dec. 1, 2025
BioWorld
1 déc. 2025
Med-tech gainers and losers for Nov. 24-26, 2025
BioWorld
1 déc. 2025
Holiday notice
BioWorld
28 nov. 2025
Kymera Therapeutics patents new STAT6 inhibitors
BioWorld
28 nov. 2025
Eli Lilly divulges new RXFP1 agonists
BioWorld
28 nov. 2025
US scientists describe new c-Raf inhibitors
BioWorld
28 nov. 2025
New EGFR inhibitors disclosed in Schrodinger patent
BioWorld
28 nov. 2025
Boehringer Ingelheim discovers new cGAS inhibitors
BioWorld
27 nov. 2025
Blueprint Medicines patents new CDK4 degradation inducers
BioWorld
27 nov. 2025
Gluetacs Therapeutics divulges new protein degradation inducers
BioWorld
27 nov. 2025
Blossomhill Therapeutics describes new macrocyclic compounds
BioWorld
27 nov. 2025
New YAP1/TEAD interaction inhibitors disclosed in Hansoh patent
Précédent
58 / 61
Suivant